Detalles de la búsqueda
1.
Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3Kß/δ inhibitors for the treatment of PTEN-deficient tumours.
Bioorg Med Chem Lett
; 27(9): 1949-1954, 2017 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28347666
2.
Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Bioorg Med Chem Lett
; 25(22): 5155-62, 2015 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26475521
3.
Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores.
J Cell Biol
; 161(2): 267-80, 2003 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-12719470
4.
Inhibiting PI3Kß with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors.
Clin Cancer Res
; 23(24): 7584-7595, 2017 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28972046
5.
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sci Transl Med
; 9(394)2017 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28615361
6.
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers.
Mol Cancer Ther
; 15(5): 877-89, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26839307
7.
Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo.
Sci Transl Med
; 8(325): 325ra17, 2016 Feb 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26865565
8.
High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Eur Urol
; 67(6): 1177-1185, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25220373
9.
Inhibition of PI3Kß signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Mol Cancer Ther
; 14(1): 48-58, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25398829
10.
Identification of a subset of human non-small cell lung cancer patients with high PI3Kß and low PTEN expression, more prevalent in squamous cell carcinoma.
Clin Cancer Res
; 20(3): 595-603, 2014 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24284056
11.
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Cancer Res
; 70(1): 288-98, 2010 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20028854
12.
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Bioorg Med Chem Lett
; 16(10): 2672-6, 2006 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16516473
13.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.
Bioorg Med Chem Lett
; 13(18): 2955-60, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12941311
14.
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.
Bioorg Med Chem Lett
; 13(18): 2961-6, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12941312
15.
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
Bioorg Med Chem Lett
; 13(18): 3021-6, 2003 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12941325
Resultados
1 -
15
de 15
1
Próxima >
>>